DDInter12 DDInter1376
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Acebutolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Acebutolol {u} (Compound) treats {v} (Disease) hypertension
Acebutolol {u} (Compound) binds {v} (Gene) ADRB2
Acebutolol {u} (Compound) causes {v} (Side Effect) Lightheadedness
Acebutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Acebutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium citrate
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orciprenaline
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Methacholine
Acebutolol {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Acebutolol (Compound) resembles Oxprenolol (Compound)
Acebutolol (Compound) treats hypertension (Disease)
Acebutolol (Compound) binds ADRB2 (Gene)
Acebutolol (Compound) causes Lightheadedness (Side Effect)
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Acebutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Acebutolol may lead to a major life threatening interaction when taken with Methacholine
Acebutolol may lead to a major life threatening interaction when taken with Dolasetron